


HEALTHCARE

## **The Dermatology Market Outlook to 2011**

By Fox Analytics

 [Table of Contents](#)

## **Fox Analytics**

Fox Analytics brings together experienced private consultants working in the field of market research, analysis, modeling and forecasting in order to deliver custom solutions, insights and analysis in pharmaceuticals and healthcare markets.

Copyright © 2007 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Dermatology Market Outlook to 2011

<b>Executive Summary</b>	<b>13</b>	
<b>Patient potential</b>	<b>13</b>	
<b>Global market analysis</b>	<b>14</b>	
<b>Pipeline analysis</b>	<b>15</b>	
<b>Competitive landscape</b>	<b>16</b>	
<b>Chapter 1</b>	<b>Patient potential</b>	<b>19</b>
<b>Summary</b>		<b>19</b>
<b>Introduction</b>		<b>20</b>
<b>Acne</b>		<b>21</b>
Overview		21
Diagnosis, treatment and management		21
Epidemiology		24
Forecast epidemiology		26
<b>Psoriasis</b>		<b>28</b>
Overview		28
Diagnosis, treatment and management		29
Epidemiology		31
Forecast epidemiology		32
<b>Infectious diseases of the skin</b>		<b>34</b>
Overview		34
Bacterial infections of the skin		34
Fungal infections of the skin		36
Viral infections of the skin		37
Diagnosis, treatment and management		38
Epidemiology		39
Viral skin infections		39
Fungal skin infections		40
Bacterial skin infections		41
Forecast epidemiology		42
Viral skin infections		42
Fungal skin infections		43
Bacterial skin infections		45



Corticosteroid treatments market analysis	100
Market dynamics	100
Key brands analysis	100
Corticosteroid treatment sales forecasts to 2011	103
<b>Anti-infective treatments</b>	<b>104</b>
Market analysis by drug class	104
Leading brands of anti-infective treatments	106
Market dynamics	106
Key brands analysis	108
Anti-infective treatment sales forecasts to 2011	113
<b>Other dermatologic treatments</b>	<b>114</b>
Leading brands of other dermatologic treatments	114
Key brands analysis	115
Other dermatologic treatment sales forecasts to 2011	119
<b>Total Therapeutic market sales forecasts to 2011</b>	<b>120</b>

## **Chapter 3                      Pipeline analysis                      123**

<b>Summary</b>	<b>123</b>
<b>Introduction</b>	<b>124</b>
<b>Key trends in R&amp;D</b>	<b>124</b>
New mechanism of action	125
Reformulations	125
Combination drugs	126
Biologics	127
<b>The therapeutic area pipeline</b>	<b>128</b>
<b>Leading drugs in development</b>	<b>130</b>
<b>Profiles of key pipeline products</b>	<b>131</b>
Phase II compounds	131
rambazole	131
Phase III compounds	132
Panaclar/BG-12	132
CNTO 1275 interleukin antagonist	134
Drugs in registration	135
Altabax (retapamulin)	135
Desonate (desonide)	137
Recently marketed drugs	138
Humira (adalimumab)	138
Oracea (doxycycline extended release sub anti-microbial dose)	141
Remicade (infliximab)	143
Taclonex (calcipotriene/betamethasone)	145
Ziana (clindamycin/tretinoin)	147
<b>Pipeline forecasts</b>	<b>149</b>
Factors affecting forecasts	149
Dermatology pipeline forecasts	149

## Chapter 4                      Competitive landscape                      153

<b>Summary</b>	<b>153</b>
<b>Introduction</b>	<b>154</b>
<b>Company market shares</b>	<b>154</b>
<b>Novartis</b>	<b>158</b>
Overview	158
Sales focus by drug class	158
Marketed product portfolio	159
R&D pipeline analysis	160
Strategic and growth analysis	161
Drivers of growth	161
Resistors of growth	161
<b>GlaxoSmithKline</b>	<b>161</b>
Overview	161
Sales focus by drug class	162
Marketed product portfolio	163
R&D pipeline analysis	164
Strategic and growth analysis	165
Drivers of growth	165
Resistors of growth	165
<b>Schering-Plough</b>	<b>166</b>
Overview	166
Sales focus by drug class	166
Marketed Product Portfolio	167
R&D pipeline analysis	168
Strategic and growth analysis	168
Drivers of growth	168
Resistors of growth	168
<b>Sanofi-Aventis</b>	<b>169</b>
Overview	169
Sales focus by drug class	169
Marketed product portfolio	170
R&D pipeline analysis	171
Strategic and growth analysis	171
Drivers of growth	171
Resistors of growth	172
<b>Johnson &amp; Johnson</b>	<b>173</b>
Overview	173
Sales focus by drug class	173
Marketed product portfolio	174
R&D pipeline analysis	176
Strategic and growth analysis	177
Drivers of growth	177
Resistors of growth	177
<b>Bayer Schering Pharma</b>	<b>178</b>
Overview	178

Sales focus by drug class	178
Marketed product portfolio	179
R&D pipeline analysis	181
Strategic and growth analysis	182
Drivers of growth	182
Resistors of growth	182
<b>Stiefel Labs</b>	<b>183</b>
Overview	183
Sales focus by drug class	183
Marketed product portfolio	184
R&D pipeline analysis	185
Strategic and growth analysis	185
Drivers of growth	185
Resistors of growth	185
<b>Roche</b>	<b>187</b>
Overview	187
Sales focus by drug class	187
Marketed product portfolio	188
R&D pipeline analysis	189
Strategic and growth analysis	189
Drivers of growth	189
Resistors of growth	190
<b>Nestle/L'Oreal</b>	<b>191</b>
Overview	191
Sales focus by drug class	191
Marketed product portfolio	192
R&D pipeline analysis	193
Strategic and growth analysis	193
Drivers of growth	193
Resistors of growth	194

## **Chapter 5                      Appendix                      197**

<b>IMS data</b>	<b>197</b>
<b>Index</b>	<b>199</b>

# List of Figures

Figure 1.1:	Typical treatment patterns in the treatment of acne	24
Figure 1.2:	Typical treatment patterns in the treatment of psoriasis	30
Figure 2.3:	Global dermatology market share by geography, 2005	57
Figure 2.4:	Sales of types of dermatology brands, 2004-5	58
Figure 2.5:	Competitive dynamics of the global dermatology market by drug class, 2005	61
Figure 2.6:	Competitive dynamics of the leading 10 brands in the global dermatology market, 2004-5	64
Figure 2.7:	Competitive dynamics of subclasses in the acne treatments market, 2004-5	67
Figure 2.8:	Competitive dynamics of the leading acne treatments in the global dermatology market, 2004-5	70
Figure 2.9:	Competitive dynamics of the leading oral acne treatments in the global dermatology market, 2004-5	72
Figure 2.10:	Competitive dynamics of the leading topical acne treatments in the global dermatology market, 2004-5	79
Figure 2.11:	Competitive dynamics of classes in the psoriasis treatments market, 2004-5	85
Figure 2.12:	Competitive dynamics of the leading psoriasis treatments in the global dermatology market, 2004-5	87
Figure 2.13:	Competitive dynamics of classes in the corticosteroid treatments market, 2004-5	97
Figure 2.14:	Competitive dynamics of the leading corticosteroid treatments in the global dermatology market, 2004-5	100
Figure 2.15:	Competitive dynamics of subclasses in the anti-infective treatments market, 2004-5	105
Figure 2.16:	Competitive dynamics of the leading anti-infective treatments in the global dermatology market, 2004-5	107
Figure 2.17:	Competitive dynamics of the leading other treatments in the global dermatology market, 2004-5	115
Figure 3.18:	Prevailing R&D approaches, 2005	124
Figure 3.19:	The dermatology pipeline by indication and stage of development, 2006	128
Figure 3.20:	Leading recently launched products and late-stage R&D in the dermatology market, 2005	130
Figure 4.21:	Competitive dynamics of the leading players in the global dermatology market, 2005	157
Figure 4.22:	Novartis' dermatology sales, 2005	158
Figure 4.23:	GSK's dermatology sales by drug class, 2005	162
Figure 4.24:	Schering-Plough's dermatology sales by drug class, 2005	166
Figure 4.25:	Sanofi-Aventis' dermatology sales by drug class, 2005	169
Figure 4.26:	J&J's dermatology sales by drug class, 2005	173
Figure 4.27:	Schering AG's dermatology sales by drug class, 2005	178
Figure 4.28:	Stiefel Labs' dermatology sales by drug class, 2005	183
Figure 4.29:	Roche's dermatology sales by drug class, 2005	187
Figure 4.30:	L'Oreal's dermatology sales by drug class, 2005	191

# List of Tables

Table 1.1:	Estimated prevalence of dermatological conditions in the seven major pharmaceutical markets, 2005	20
Table 1.2:	Estimated prevalence of clinical acne across seven major markets, 2005	25
Table 1.3:	Forecast epidemiology of clinical acne across the seven major markets, 2005-11	27
Table 1.4:	Estimated prevalence of psoriasis across seven major markets, 2005	32
Table 1.5:	Forecast epidemiology of psoriasis across the seven major markets, 2005-11	33
Table 1.6:	Estimated prevalence of infectious diseases (viral) of the skin across seven major markets, 2005	40
Table 1.7:	Estimated prevalence of infectious diseases (fungal) of the skin across seven major markets, 2005	41
Table 1.8:	Estimated prevalence of infectious diseases (bacterial) of the skin across seven major markets, 2005	42
Table 1.9:	Forecast epidemiology of infectious diseases (viral) of the skin across the seven major markets, 2005-11	43
Table 1.10:	Forecast epidemiology of infectious diseases (fungal) of the skin across the seven major markets, 2005-11	44
Table 1.11:	Forecast epidemiology of infectious diseases (bacterial) of the skin across the seven major markets, 2005-11	45
Table 1.12:	Estimated prevalence of atopic dermatitis across seven major markets, 2005	47
Table 1.13:	Forecast epidemiology of dermatitis across the seven major markets, 2005-11	49
Table 1.14:	Estimated prevalence of rosacea across seven major markets, 2005	51
Table 1.15:	Forecast epidemiology of rosacea across the seven major markets, 2005-11	53
Table 2.16:	The global dermatology market by drug class, 2001-5	59
Table 2.17:	Leading brands in the global dermatology market, 2004-5	62
Table 2.18:	The global acne market by drug class, 2001-5	66
Table 2.19:	Leading acne treatments in the global dermatology market,	68
Table 2.20:	Leading oral acne treatments in the global dermatology market, 2004-5	71
Table 2.21:	Leading topical acne treatments in the global dermatology market, 2004-5	78
Table 2.22:	Acne treatments sales forecast, 2005-11	83
Table 2.23:	The global psoriasis market by drug class, 2001-5	84
Table 2.24:	Leading psoriasis treatments in the global dermatology market, 2004-5	86
Table 2.25:	Psoriasis treatments sales forecast, 2005-11	95
Table 2.26:	The global corticosteroid market by drug class, 2001-5	96
Table 2.27:	Leading corticosteroid treatments in the global dermatology market, 2004-5	99
Table 2.28:	Corticosteroid treatment sales forecast, 2005-11	103
Table 2.29:	The global anti-infective market by drug class, 2001-5	104
Table 2.30:	Leading anti-infective treatments in the global dermatology market, 2004-5	106
Table 2.31:	Anti-infective treatment sales forecast, 2005-11	113
Table 2.32:	Leading other treatments in the global dermatology market, 2004-5	114
Table 2.33:	Other dermatologic treatment sales forecast, 2005-11	119
Table 2.34:	Therapeutic sales forecasts by drug class, 2005-11	120
Table 3.35:	Dermatology pipeline forecasts, 2005-11	149
Table 4.36:	Leading players in the global dermatology market, 2004-5	154
Table 4.37:	Novartis' dermatology product portfolio, 2004-5	159
Table 4.38:	Novartis' dermatology R&D product pipeline, 2006	160
Table 4.39:	GSK's dermatology product portfolio, 2004-5	163
Table 4.40:	GSK's dermatology R&D product pipeline, 2006	164

Table 4.41:	Schering-Plough's dermatology product portfolio, 2004-5	167
Table 4.42:	Sanofi-Aventis' dermatology product portfolio, 2004-5	170
Table 4.43:	Johnson & Johnson's dermatology product portfolio, 2004-5	175
Table 4.44:	Johnson & Johnson's dermatology R&D product pipeline, 2006	176
Table 4.45:	Schering AG's dermatology product portfolio, 2004-5	180
Table 4.46:	Schering AG's dermatology R&D product pipeline, 2006	181
Table 4.47:	Stiefel Lab's dermatology product portfolio, 2004-5	184
Table 4.48:	Roche's dermatology product portfolio, 2004-5	188
Table 4.49:	Roche's dermatology R&D product pipeline, 2006	189
Table 4.50:	Nestle/L'Oreal's dermatology product portfolio, 2004-5	192